Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer
- Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immunooncology and small molecules
- Adcendo building a world class team of experienced biotech & pharma executives and renowned leaders in the ADC field
Copenhagen, Denmark, May 3, 2022 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers, today announces the appointment of Dominik Mumberg, PhD, as Chief Scientific Officer (CSO).
